Neurotech International Limited (ASX:NTI)

Australia flag Australia · Delayed Price · Currency is AUD
0.0120
-0.0010 (-7.69%)
Mar 10, 2026, 3:49 PM AEST
-63.64%
Market Cap 16.85M
Revenue (ttm) 7.07M
Net Income (ttm) -3.85M
Shares Out 1.30B
EPS (ttm) -0.00
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 2,162,076
Average Volume 1,017,058
Open 0.0120
Previous Close 0.0130
Day's Range 0.0120 - 0.0120
52-Week Range 0.0120 - 0.0400
Beta 0.04
RSI 45.91
Earnings Date Feb 24, 2026

About Neurotech International

Neurotech International Limited, a clinical-stage biopharmaceutical development company, engages in the research, design, development, and manufacture of medical devices and solutions in Australia. The company focuses on development and commercialization of NTI164 for multiple paediatric neurological disorders; and Mente, a clinically proven home therapy aimed at enhancing engagement and relaxation in autistic children exhibiting elevated delta band brain activity. It also engages in executing medical research projects; and developing technolog... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2016
Country Australia
Stock Exchange Australian Securities Exchange
Ticker Symbol NTI
Full Company Profile

Financial Performance

In fiscal year 2025, Neurotech International's revenue was 2.44 million, a decrease of -23.07% compared to the previous year's 3.18 million. Losses were -10.60 million, 109.1% more than in 2024.

Financial Statements

News

There is no news available yet.